EORTC – Understanding long-term quality of life after completion of an adjuvant treatment for melanoma

EORTC – European Organisation for Research and Treatment of Cancer shared on LinkedIn:

” Have you read our latest publication in The Lancet Oncology?

Understanding patients’ health-related quality of life after completion of an adjuvant treatment for melanoma is important.

The research area concerns patients who are likely to become cancer survivors and would be impacted by potential long-term adverse effects. This publication provides results on the long-term health-related quality of life of melanoma patients treated with a PD-1 inhibitor. ”

‘Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial‘

Source: EORTC/LinkedIn